Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Induction of Clinical Response Using Rifaximin in Crohn's Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by University of Washington
Valeant Pharmaceuticals International, Inc.
Information provided by (Responsible Party):
Scott Lee, University of Washington Identifier:
First received: January 16, 2008
Last updated: May 10, 2016
Last verified: May 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: December 2017
  Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)